持田製薬(株)の貸借残高情報
主市場 | 業種 | 証券コード/EDINET | 英名称 |
---|
東証PRM | 医薬品 | 4534/E00947 | - |
公表日 | 公表 | 貸付残高 | 前週比 | 新規貸付成約高 | 前週比 | 借入残高 | 前週比 | 新規借入成約高 | 前週比 |
---|
2019/11/15 | 日証協 | 152,955株 | -4.02% | 38,760株 | +61.3% | 166,910株 | -11.74% | 13,600株 | -53.85% |
2019/11/08 | 日証協 | 159,355株 | -7.29% | 24,030株 | +72.95% | 189,110株 | -14.7% | 29,467株 | -20.86% |
2019/11/01 | 日証協 | 171,888株 | -3.48% | 13,894株 | -64.34% | 221,706株 | -16.53% | 37,232株 | +109.5% |
2019/10/25 | 日証協 | 178,093株 | +43.06% | 38,967株 | -43.55% | 265,614株 | +27.59% | 17,772株 | -87.45% |
2019/10/18 | 日証協 | 124,491株 | -32.92% | 69,028株 | -61.44% | 208,184株 | +2.38% | 141,630株 | +208.36% |
2019/10/11 | 日証協 | 185,595株 | +78.56% | 179,037株 | +87.21% | 203,342株 | +0.77% | 45,930株 | -24.64% |
2019/10/04 | 日証協 | 103,937株 | +132.53% | 95,632株 | +136.7% | 201,784株 | +8.68% | 60,944株 | -44.39% |
2019/09/27 | 日証協 | 44,699株 | -77.67% | 40,402株 | -26.46% | 185,666株 | -16.5% | 109,598株 | +405.01% |
2019/09/20 | 日証協 | 200,145株 | +9.86% | 54,937株 | +36.23% | 222,354株 | -11.5% | 21,702株 | -46.39% |
2019/09/13 | 日証協 | 182,176株 | +0.01% | 40,326株 | -42.64% | 251,254株 | -18.76% | 40,478株 | +7.65% |
2019/09/06 | 日証協 | 182,157株 | -10.61% | 70,307株 | +277.77% | 309,276株 | -12.47% | 37,600株 | -49.61% |
2019/08/30 | 日証協 | 203,778株 | +2.93% | 18,611株 | +4.56% | 353,323株 | +2% | 74,613株 | -21.21% |
2019/08/23 | 日証協 | 197,974株 | +2.18% | 17,800株 | -74.95% | 346,410株 | +7.82% | 94,700株 | +22.19% |
2019/08/16 | 日証協 | 193,757株 | +17.78% | 71,051株 | +66.79% | 321,293株 | +15.7% | 77,500株 | -24.24% |
2019/08/09 | 日証協 | 164,506株 | -0.51% | 42,600株 | +58.36% | 277,693株 | +3.35% | 102,297株 | +204.49% |
2019/08/02 | 日証協 | 165,341株 | +12.91% | 26,900株 | +85.52% | 268,692株 | +2.25% | 33,596株 | -30% |
2019/07/26 | 日証協 | 146,441株 | -9.12% | 14,500株 | +155.1% | 262,792株 | +1.47% | 47,996株 | -44.89% |
2019/07/19 | 日証協 | 161,141株 | -7.57% | 5,684株 | -56.28% | 258,992株 | +28.35% | 87,096株 | +39.59% |
2019/07/12 | 日証協 | 174,341株 | -20.52% | 13,000株 | -68.82% | 201,792株 | -3.21% | 62,392株 | +87.45% |
※株式分割は考慮していませんのでご注意ください。
Page Top